ALAB vs NVDA

ALAB demonstrates strong financial health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and profitability. The company exhibits exceptional growth momentum with 91.8% YoY revenue growth and 83.6% earnings growth, supported by high margins (75.69% gross, 25.70% net) and a pristine balance sheet with negligible debt (Debt/Equity: 0.02). Despite a high valuation (P/E: 98.61), the intrinsic value estimate of $35.99 and Graham Number of $14.83 suggest significant upside potential if growth is sustained. However, recent insider selling and a bearish technical trend introduce near-term caution. Price trades at a 234.3% premium to fair value estimate ($35.99), limiting near-term upside from a valuation perspective.

NVDA exhibits strong financial health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and solvency. While the current price of $182.08 is significantly above the Graham Number ($26.71) and the growth-based intrinsic value ($144.55), the stock is fundamentally undervalued relative to its growth, as evidenced by a PEG ratio of 0.72 and a highly attractive Forward P/E of 16.38. The company's elite profitability margins (55.6% profit margin) and minimal debt (0.07 D/E) provide a massive cushion for volatility. Despite bearish insider sentiment and short-term technical weakness, the long-term growth trajectory remains exceptionally strong.